Spotlight
Clinical Role
Clinical
Supplement Spotlight
CME/CE
Subscribe
Targeted Therapy Treatment Innovations in AML : Episode 3
Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
Alexandra S. Wolff, PharmD, BCOP, discusses use of IDH1 and IDH2 inhibitors in newly diagnosed AML patients and highlights recently released trial data.
EP: 1.Role of First Generation FLT3 Inhibitors in AML
EP: 2.Role of Second Generation FLT3 Inhibitors in AML
Now Viewing
EP: 3.Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
EP: 4.Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
EP: 5.Role of Venetoclax in Treatment of AML
EP: 6.Part 1: Practical Considerations For Venetoclax in AML
EP: 7.Part 2: Practical Considerations For Venetoclax in AML
EP: 8.5-Year Follow-Up Data For CPX-351 in AML
EP: 9.CPX-351 in Clinical Practice For AML
Related Videos
Related Content
